Phreesia, Inc. (NYSE:PHR - Get Free Report) SVP Amy Beth Vanduyn sold 25,447 shares of the business's stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $20.93, for a total value of $532,605.71. Following the transaction, the senior vice president now owns 93,470 shares in the company, valued at $1,956,327.10. The trade was a 21.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Phreesia Stock Performance
PHR opened at $21.15 on Friday. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $29.16. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.77 and a quick ratio of 1.77. The stock's 50 day simple moving average is $20.30 and its 200 day simple moving average is $21.79. The stock has a market cap of $1.22 billion, a P/E ratio of -11.75 and a beta of 0.98.
Phreesia (NYSE:PHR - Get Free Report) last posted its earnings results on Wednesday, September 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.06. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. The firm had revenue of $102.12 million for the quarter, compared to analyst estimates of $101.76 million. As a group, equities analysts anticipate that Phreesia, Inc. will post -1.23 EPS for the current fiscal year.
Institutional Investors Weigh In On Phreesia
Vladimir Lenin was right…
From Porter & Company | Ad
The Magnificent 7 could be in for a world of pain…
And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock.
The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on.
It’s called The Final Frontier.
Including the name of the #1 company to buy.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Champlain Investment Partners LLC lifted its stake in Phreesia by 4.1% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company's stock valued at $57,062,000 after buying an additional 97,847 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Phreesia by 3.0% during the 3rd quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company's stock worth $31,495,000 after purchasing an additional 42,973 shares during the period. State Street Corp lifted its stake in shares of Phreesia by 7.1% during the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company's stock worth $30,256,000 after purchasing an additional 88,517 shares during the period. Geode Capital Management LLC lifted its stake in shares of Phreesia by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company's stock worth $28,397,000 after purchasing an additional 55,934 shares during the period. Finally, TimesSquare Capital Management LLC lifted its stake in shares of Phreesia by 2.3% during the 3rd quarter. TimesSquare Capital Management LLC now owns 868,409 shares of the company's stock worth $19,791,000 after purchasing an additional 19,395 shares during the period. Hedge funds and other institutional investors own 92.10% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have issued reports on PHR shares. JMP Securities reiterated a "market outperform" rating and set a $30.00 target price on shares of Phreesia in a research report on Thursday, September 5th. Royal Bank of Canada reiterated a "sector perform" rating and set a $23.00 target price on shares of Phreesia in a research report on Friday, September 27th. Canaccord Genuity Group reiterated a "buy" rating and set a $34.00 target price on shares of Phreesia in a research report on Thursday, September 5th. JPMorgan Chase & Co. boosted their target price on Phreesia from $27.00 to $28.00 and gave the stock an "overweight" rating in a research report on Monday, September 9th. Finally, DA Davidson restated a "buy" rating and issued a $32.00 price target on shares of Phreesia in a report on Thursday, September 5th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, Phreesia currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.42.
View Our Latest Report on PHR
Phreesia Company Profile
(
Get Free Report)
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
